Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04560322 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Eligibility criteria expanded, about 48 words · Secondary endpoints: details revised at 6 of 7 entries · Study description expanded, about 7 words · 2 more Show 5 more changesShow less
    • Eligibility criteria expanded, about 48 words
    • Secondary endpoints: details revised at 6 of 7 entries
    • Study description expanded, about 7 words
    • Site details revised at 3 of 3 sites
    • Publications: details revised at 1 of 1 entry
  2. Primary completion pushed from Mar 1, 2026 to Mar 1, 2028 Completion pushed from Mar 1, 2027 to Mar 1, 2029v7 Show 1 more changeShow less
    • Completion pushed from Mar 1, 2027 to Mar 1, 2029
  3. Re-verified, no change to tracked fieldsv6
  4. Primary completion date: Mar 1, 2025 to Mar 1, 2026 Completion date: Mar 1, 2025 to Mar 1, 2027v5 Show 1 more changeShow less
    • Completion date: Mar 1, 2025 to Mar 1, 2027
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Mar 1, 2022 to Mar 1, 2025 Completion date: Mar 1, 2024 to Mar 1, 2025v3 Show 1 more changeShow less
    • Completion date: Mar 1, 2024 to Mar 1, 2025
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2020 to Oct 19, 2020 · Interventions: Ibrutinib (Drug), Obinutuzumab (Drug), Venetoclax (Drug) to Acalabrutinib (Drug), Obinutuzumab (Drug), Venetoclax (Drug) · Eligibility criteria revised · 4 morev2 Show 7 more changesShow less
    • Start date changed from estimate of Sep 2020 to Oct 19, 2020
    • Interventions: Ibrutinib (Drug), Obinutuzumab (Drug), Venetoclax (Drug) to Acalabrutinib (Drug), Obinutuzumab (Drug), Venetoclax (Drug)
    • Eligibility criteria revised
    • Secondary endpoints revised (7)
    • Study description revised
    • Site details revised at 3 of 3 sites
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: * obinutuzumab * venetoclax * acalabrutinib
Trial Details
NCT Number NCT04560322
Lead Sponsor Massachusetts General Hospital
Collaborators: Genentech, Inc.
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov